Palleon's first CSO ex­plains how they (and she) got here; En­ter­prise taps Roche and No­var­tis vet David Mor­ris as CMO

For a decade, Li Peng built an­ti­bod­ies at the Med­Im­mune labs out­side DC: A bis­pe­cif­ic Am­gen is now test­ing in GI can­cer, an Il-5 for cer­tain kinds of asth­ma, an­oth­er that im­pacts nat­ur­al killer cells near tu­mors.

It was a sen­si­ble ap­proach. The first an­ti­body to treat can­cer was in­tro­duced not long be­fore she be­gan grad school and the hunt has played a ma­jor role in biotech for much of Peng’s ca­reer.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN